logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Japanese startup RevolKa secures $1.4 M in Series A extension funding to advance drug discovery programmes for rare diseases, co-led by D3 LLC and TOHOKU University Venture Partners.

May 20, 2025•7 months ago

Amount Raised

$1.4 Million

SendaiBiotechnology

Investors

Deepcore Inc.Tohoku University Venture PartnersD3 Llc

Description

RevolKa Ltd. has raised $1.4 million in Series A extension funding to further its drug discovery programmes for rare diseases. This round was co-led by D3 LLC and TOHOKU University Venture Partners, with participation from DEEPCORE Inc. The funding will also support collaborative partnering efforts to enhance their AI-powered protein engineering technology

Company Information

Company

RevolKa

Location

Sendai, Miyagi Prefecture, Japan

About

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers